Showing 261 - 280 results of 20,969 for search '(( a nn decrease ) OR ((( 50 ((we decrease) OR (a decrease)) ) OR ( a fold decrease ))))', query time: 0.55s Refine Results
  1. 261

    Decreased myofibroblasts in the peritumoral region and high expression of MMP-7 in Pan02 S.C. tumor of <i>S100a4-Cre; Ext1</i><sup><i>f/f</i></sup> mice. by Ayumi Niwa (6256790)

    Published 2023
    “…Decreased gene expression is indicated in blue, and increased gene expression is indicated in red (fold change > 2, moderate t-test, <i>P</i> < 0.05; N = 3 for each cohort). …”
  2. 262

    FTY720 treatment decreased tumor growth in a xenograft model of hepatoblastoma. by Laura L. Stafman (6577184)

    Published 2019
    “…There was a trend toward decreased Ki67 staining in FTY720-treated tumors (p = 0.29). …”
  3. 263

    Advancing the science of NOWS research. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  4. 264

    Protocol measures. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  5. 265

    Cry variables. by Sarah E. Maylott (14560785)

    Published 2024
    “…It is not known which infants will develop NOWS, therefore, the current hospital standard-of-care dictates a 96-hour observational hold. Understanding which infants will develop NOWS soon after birth could reduce hospital stays for infants who do not develop NOWS and decrease burdens on hospitals and clinicians. …”
  6. 266

    DataSheet_2_A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.docx by Yu-Ying Shi (15975992)

    Published 2023
    “…Introduction<p>Our previous research has found that degradation of palmitoyltransferase in tumor cells using a linear peptide PROTAC leads to a significant decrease in PD-L1 expression in tumors. …”
  7. 267

    DataSheet_1_A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.docx by Yu-Ying Shi (15975992)

    Published 2023
    “…Introduction<p>Our previous research has found that degradation of palmitoyltransferase in tumor cells using a linear peptide PROTAC leads to a significant decrease in PD-L1 expression in tumors. …”
  8. 268
  9. 269
  10. 270
  11. 271
  12. 272
  13. 273
  14. 274
  15. 275
  16. 276
  17. 277
  18. 278
  19. 279

    DataSheet_1_Decreased TCF1 and BCL11B expression predicts poor prognosis for patients with chronic lymphocytic leukemia.docx by Taotao Liang (9944552)

    Published 2022
    “…<p>T cell immune dysfunction is a prominent characteristic of chronic lymphocytic leukemia (CLL) and the main cause of failure for immunotherapy and multi-drug resistance. …”
  20. 280